[CDTX] Cidara Therapeutics, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 11 Change: 0.8 (7.84%)
Ext. hours: Change: 0 (0%)

chart CDTX

Refresh chart

Strongest Trends Summary For CDTX

CDTX is in the long-term down -91% below S&P in 6 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities41.41 M Cash From Investing Activities-30 K Cash From Operating Activities-6.05 M Gross Profit
Net Profit-6.74 M Operating Profit-6.73 M Total Assets60.78 M Total Current Assets58.4 M
Total Current Liabilities3.81 M Total Debt Total Liabilities3.84 M Total Revenue
Technical Data
High 52 week4.5 Low 52 week1.25 Last close1.89 Last change4.42%
RSI53.13 Average true range0.12 Beta0.84 Volume27 K
Simple moving average 20 days0.35% Simple moving average 50 days7.62% Simple moving average 200 days-11.76%
Performance Data
Performance Week6.78% Performance Month-9.57% Performance Quart9.88% Performance Half-26.17%
Performance Year-52.63% Performance Year-to-date-19.57% Volatility daily3.42% Volatility weekly7.65%
Volatility monthly15.67% Volatility yearly54.3% Relative Volume259.89% Average Volume477.68 K
New High New Low

News

2019-11-07 21:17:06 | Cidara Provides Corporate Update and Reports Third Quarter 2019 Financial Results

2019-11-05 08:00:00 | Cidara Therapeutics Hosting Key Opinion Leader Meeting on Rezafungin and Cloudbreak Programs

2019-10-06 20:22:34 | Weekly CFO Buys Highlight

2019-10-03 10:22:55 | Cidara Therapeutics to Present New Clinical and Preclinical Data at Two Upcoming Medical Conferences

2019-10-01 10:07:00 | Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019

2019-09-16 16:05:00 | Cidara Therapeutics to Participate in Two Upcoming Investor Conferences

2019-09-04 14:37:34 | Wedbush Recommends Buying Cidara Shares After Rezafungin Deal

2019-09-04 12:07:41 | A Look At Benzinga Pro's Most-Searched Tickers For September 4, 2019

2019-09-03 12:31:21 | Edited Transcript of CDTX earnings conference call or presentation 8-Nov-17 9:05pm GMT

2019-09-03 06:41:00 | Cidara Therapeutics's stock rockets after commercialization deal with a potential value of up to $568 million

2019-08-21 08:00:00 | Cidara Therapeutics to Present Data from its Cloudbreak Antiviral Program at the Options X for the Control of Influenza Conference

2019-08-08 16:07:49 | Cidara Provides Corporate Update and Reports Second Quarter 2019 Financial Results

2019-08-07 07:30:00 | Cidara Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference

2019-07-29 07:00:00 | Cidara Therapeutics Reports Positive Topline Results in Phase 2 STRIVE B Trial of Antifungal Rezafungin

2019-07-01 09:13:00 | X-Biotix Therapeutics Joins Antimicrobials Working Group

2019-06-20 11:13:00 | Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2019

2019-06-19 13:16:12 | Imagine Owning Cidara Therapeutics NASDAQ:CDTX And Trying To Stomach The 85% Share Price Drop

2019-06-07 09:27:00 | Antimicrobials Working Group Commends Senator Isakson and Senator Casey for Introducing Legislation to Improve Access to Innovative Therapies to Fight Drug-Resistant Infections

2019-06-05 08:00:00 | Cidara Therapeutics to Present New Data on Rezafungin and its Cloudbreak Antiviral Candidate for Influenza at ASM Microbe 2019

2019-05-22 09:00:01 | What Makes Cidara Therapeutics CDTX a New Buy Stock

2019-05-09 19:54:23 | Cidara Therapeutics: 1Q Earnings Snapshot

2019-05-09 16:13:53 | Cidara Provides Corporate Update and Reports First Quarter 2019 Financial Results

2019-04-16 08:00:00 | Cidara Therapeutics Highlights New Data from Multiple Rezafungin Studies Presented at ECCMID 2019

2019-04-15 08:00:00 | Cidara Therapeutics Selects First Clinical Development Candidate from its Cloudbreak Influenza Antiviral Program

2019-04-12 10:08:00 | Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology and Infectious Diseases ECCMID

2019-04-03 16:04:00 | Cidara Therapeutics to Present at the 18th Annual Needham Healthcare Conference

2019-03-26 08:00:00 | Cidara Therapeutics Announces Multiple Presentations at the 29th European Congress of Clinical Microbiology and Infectious Diseases ECCMID

2019-03-07 08:00:00 | Cidara Therapeutics Announces Rezafungin Presentations at the 2019 European Society for Blood and Marrow Transplantation Meeting

2019-03-04 12:19:18 | Have Insiders Been Buying Cidara Therapeutics, Inc. NASDAQ:CDTX Shares?

2019-02-28 16:24:36 | Cidara Provides Corporate Update and Reports Fourth Quarter and Full Year 2018 Financial Results

2019-02-05 08:00:00 | Cidara Therapeutics Announces Rezafungin Presentations at the 2019 Transplantation and Cellular Therapy TCT Meeting

2019-01-17 10:00:00 | Antimicrobials Working Group Announces Updates to Leadership Team

2018-12-21 09:54:04 | How Does Investing In Cidara Therapeutics, Inc. NASDAQ:CDTX Impact The Volatility Of Your Portfolio?

2018-12-03 08:00:00 | Cidara Therapeutics Appoints James Levine as CFO and Jessica Oien as General Counsel and Secretary

2018-11-27 08:38:01 | Cidara Therapeutics CDTX Enters Oversold Territory

2018-11-27 08:00:00 | Cidara Therapeutics to Present New Data at ASH 2018 Highlighting Potential of Rezafungin to Prevent Invasive Fungal Infections in Bone Marrow Transplant Patients

2018-11-14 08:30:00 | New Research Coverage Highlights Alcentra Capital, VeriSign, Americold Realty Trust, Internet Initiative Japan, DAVIDsTEA, and Cidara Therapeutics — Consolidated Revenues, Company Growth, and Expectations for 2018

2018-11-12 08:00:00 | Cidara Therapeutics Named a San Diego Metro Area Top Workplace for Second Consecutive Year

2018-11-08 17:38:29 | Cidara Therapeutics: 3Q Earnings Snapshot

2018-11-08 17:23:17 | Cidara Provides Corporate Update and Reports Third Quarter 2018 Financial Results

2018-10-24 08:00:00 | Cidara Therapeutics to Present New Data Highlighting Its Cloudbreak Immunotherapy Platform at the 2018 World Antimicrobial Resistance Congress

2018-10-15 08:00:00 | Cidara Therapeutics to Present New Rezafungin Data at the 2018 Hot Topics in Infectious Diseases Conference

2018-10-04 08:00:00 | Cidara Therapeutics Presents Results from Successful Phase 2 STRIVE Trial Evaluating Rezafungin at IDWeek 2018

2018-09-27 08:00:00 | Cidara Therapeutics Initiates Phase 3 Trial of Lead Antifungal Rezafungin for Treatment of Invasive Candida Infections

2018-09-25 13:16:57 | Shareholders Should Check If Insiders Own Shares In Cidara Therapeutics Inc NASDAQ:CDTX

2018-09-25 08:00:00 | FDA Grants QIDP and Fast Track Designations to Cidara Therapeutics’ Rezafungin Prophylaxis Development Program

2018-09-24 16:05:00 | Cidara Therapeutics to Present at Two Upcoming Investor Conferences

2018-09-12 16:02:00 | Cidara Therapeutics Appoints David Gollaher, Ph.D., to Board of Directors

2018-09-12 08:00:00 | Cidara Therapeutics to Present Data on Lead Antifungal Rezafungin at IDWeek 2018

2018-09-04 08:00:00 | Cidara Therapeutics to Present New Cloudbreak Data at the ESCMID/ASM Conference and 16th Annual Discovery on Target Meeting